COMPANY

Virogen Biotechnology

HQ: Pleasanton, CA source · virogenbio.com ↗ · West Coast

Location: Pleasanton, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Mycosis Fungoides Stage IV Melanoma T-cell Lymphomas T-cell Leukemia Sezary Syndrome Cutaneous T-cell Lymphoma Melanoma VG712 A-dmDT390-bisFv(UCHT1)

5Trials (company is sponsor)

Timeline

Jul 30, 2026 Trial start Phase 2: A Study of VG712 in Patients With Mycosis Fungoides source ↗
2026-05 Trial start Phase 2: Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides source ↗
2017-01 Trial start Phase 1/Phase 2: A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma source ↗
2014-02 Trial start Phase 1/Phase 2: A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma source ↗
2008-01 Trial start Phase 2: A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) source ↗

Upcoming milestones

Dec 30, 2030 (ESTIMATED) · Phase 2 · A Study of VG712 in Patients With Mycosis Fungoides · NCT07529405

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT02943642	Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides	Phase 2	Withdrawn	2026-05	May 13, 2026 (actual)
NCT07529405	A Study of VG712 in Patients With Mycosis Fungoides	Phase 2	Not yet recruiting	Jul 30, 2026	Dec 30, 2030 (estimated)
NCT02990416	A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	2017-01	2018-02 (estimated)
NCT00611208	A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)	Phase 2	Completed	2008-01	2015-02 (actual)
NCT01888081	A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma	Phase 1/Phase 2	Terminated	2014-02	2020-12 (estimated)